• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Microbiol . Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection

tetano

Editor, Senior Moderator
Nat Microbiol


. 2025 Jan 15.
doi: 10.1038/s41564-024-01908-2. Online ahead of print. Proteolysis-targeting influenza vaccine strains induce broad-spectrum immunity and in vivo protection

Jinying Shen[SUP] #[/SUP][SUP] 1 [/SUP], Jing Li[SUP] #[/SUP][SUP] 1 [/SUP], Quan Shen[SUP] #[/SUP][SUP] 1 2 [/SUP], Jihuan Hou[SUP] #[/SUP][SUP] 1 [/SUP], Chunhe Zhang[SUP] #[/SUP][SUP] 1 [/SUP], Haiqing Bai[SUP] #[/SUP][SUP] 3 4 [/SUP], Xiaoni Ai[SUP] #[/SUP][SUP] 5 [/SUP], Yinlei Su[SUP] 1 [/SUP], Zihao Wang[SUP] 1 [/SUP], Yunfei Zhang[SUP] 1 [/SUP], Beibei Xu[SUP] 1 [/SUP], Jiawei Hao[SUP] 1 [/SUP], Ping Wang[SUP] 1 [/SUP], Qisi Zhang[SUP] 1 [/SUP], Adam Yongxin Ye[SUP] 6 [/SUP], Zhen Li[SUP] 1 7 [/SUP], Tang Feng[SUP] 8 [/SUP], Le Li[SUP] 1 [/SUP], Fei Qi[SUP] 1 [/SUP], Qikai Wang[SUP] 1 [/SUP], Yacong Sun[SUP] 1 [/SUP], Chengyao Liu[SUP] 1 [/SUP], Xuetong Xi[SUP] 1 2 [/SUP], Lei Yan[SUP] 9 [/SUP], Hanhui Hong[SUP] 10 [/SUP], Yuting Chen[SUP] 1 [/SUP], Xin Xie[SUP] 3 4 [/SUP], Jing Xie[SUP] 8 11 [/SUP], Xiaoheng Liu[SUP] 11 [/SUP], Ruikun Du[SUP] 12 [/SUP], Roberto Plebani[SUP] 13 [/SUP], Lihe Zhang[SUP] 5 [/SUP], Demin Zhou[SUP] 5 7 [/SUP], George Church[SUP] 6 [/SUP], Longlong Si[SUP] 14 15 [/SUP]



Affiliations
Abstract

Generating effective live vaccines from intact viruses remains challenging owing to considerations of safety and immunogenicity. Approaches that can be applied in a systematic manner are needed. Here we created a library of live attenuated influenza vaccines by using diverse cellular E3 ubiquitin ligases to generate proteolysis-targeting (PROTAR) influenza A viruses. PROTAR viruses were engineered to be attenuated by the ubiquitin-proteasome system, which mediates viral protein degradation in conventional host cells, but allows efficient replication in engineered cell lines for large-scale manufacturing. Depending on the degron-E3 ligase pairs, viruses showed varying degrees of attenuation. In animal models, PROTAR viruses were highly attenuated and elicited robust, broad, strain-dependent humoral, mucosal and cellular immunity. In addition, they provided cross-reactive protection against homologous and heterologous viral challenges. This study provides a systematic approach for developing safe and effective vaccines, with potential applications in designing live attenuated vaccines against other pathogens.


 
Back
Top Bottom